[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Instituto de Investigación Hospital Universitario La Paz\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":260},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,47,78,103,133,157,186,213,233],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100592983","phase-4-inhaled-sedation-in-critically-ill-patients-100592983",false,"NCT07000526","Inhaled Sedation in Critically Ill Patients","Inhaled Sedation in Critically Ill Patients: a Multicentre Randomized Clinical Trial","IS-CRITIC","Inclusion Criteria:\n\n\\- Adult patients receiving mechanical ventilation, with an anticipated duration \\>48 hours after randomization, and requiring deep sedation (target RASS between -3 and -5).\n\nExclusion Criteria:\n\n* Contraindication to isoflurane or propofol\n* Patients with maternal ancestry from Venezuela, due to the potential presence of an mt-ND4 gene mutation associated with neurological injury after exposure to certain volatile anaesthetic agents\n* Significant air leak, defined as a leak exceeding 30% of the delivered minute ventilation\n* Allergy to isoflurane or propofol\n* Cardiopulmonary arrest\n* History of ventricular tachycardia or long QT syndrome\n* Tidal volume \\\u003C 300 mL or PaCO₂ \\> 50 mmHg at the time of randomization.\n* Invasive mechanical ventilation for more than 48 hours at the time of randomization.\n* Pregnancy\n* Breast feeding\n* Acute neurological condition\n* Patients expected to require repeated surgical interventions during their ICU stay.\n* ECMO\n* ECCO2R\n* Active humidification strictly required\n* Neuromuscular disease or high spinal cord injury likely to prevent discontinuation of mechanical ventilation due to baseline condition\n* Requirement for benzodiazepine use for a specific indication\n* Burns\n* Life expectancy less than 48 hours, or patients with such a level of severity that death during the ICU stay is considered highly likely.\n* Any condition (e.g., blindness, deafness, dementia) or language barrier that prevents the administration of delirium or cognitive assessment scales.\n* Lack of informed consent","ALL","18 Years","80 Years",{"count":21,"type":22},620,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The proposal of this study is to compare inhaled sedation with isoflurane administered via the Sedaconda ACD-S system with intravenous sedation with propofol. Patients will be randomized 1:1 to receive either inhaled sedation with isoflurane administered via the Sedaconda ACD device (Sedana Medical, Uppsala, Sweden) or intravenous propofol. The primary endpoint is the number of ventilator-free days at 28 days after randomization.",[28,29],"Sedation","Airway Extubation",[31,32,33],"Inhaled sedation","Mechanical ventilation","Delirium","RECRUITING","2026-06-26",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":38},"2025-12-15",{"date":42,"type":22},"2027-12",{"name":44,"class":45},"Instituto de Investigación Hospital Universitario La Paz","OTHER",22,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":18,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100607861","a-privacy-protecting-environment-for-child-transplants-health-related-and-genomic-data-integration-in-the-european-reference-network-100607861","NCT07194057","\"A Privacy-protecting Environment for Child Transplants Health Related and Genomic Data Integration in the European Reference Network\"","Protect_Child","Inclusion Criteria:\n\n* ● Paediatric patients (6 months to 18 years old) with liver or kidney transplant.\n\nBoth patients with de novo transplantation or in follow-up can be included in the study.\n\n* For the retrospective cohort, only patients within the first 5 years after transplantation will be included.\n* Patients and\u002For parents agreeing to participate in the study and provide consent for the obtention of clinical data and samples for genomic and methylomic analysis and the use of the information according to the protocol.\n\nExclusion Criteria:\n\n* Patients that are not being followed up in the clinical site.\n* Subjects alternating between different clinical sites. Subjects\u002FTutors that don't understand the informed consent form.\n* Subject or their legally authorized representative does not sign the informed consent document.\n* Re-transplantation or AB0-incompatible transplantation.","6 Months",{"count":56,"type":22},200,"OBSERVATIONAL","Protect\\_Child\\_101 is an observational study to be performed in children that have undergone a liver or renal transplant.\n\nThe aim of this study is to analyse small variations in the genetic material (DNA) of transplanted children. The investigators will also study a type of chemical 'marks' called methylations, which do not change the DNA itself, but can affect how it functions. These marks can influence how certain diseases develop or how the body responds to transplantation.\n\nSpecifically, investigators seek to discover:\n\n* Whether there are genetic or epigenetic (methylation) alterations that may explain why some children develop serious diseases that require transplantation.\n* If these alterations can help us predict possible complications after transplantation, such as organ rejection, infections, organ failure, cancer development.\n\nWithin this study, data from the child's medical history will be collected. The data to be collected are demographic data (gender, age, ethnicity), clinical data, personal and family history possibly related to his\u002Fher disease, course and evolution of the disease, and complementary and laboratory examinations collected from his\u002Fher clinical history.\n\nThe only non-routine tests to be performed will be the genomic and methylomic tests. Nevertheless, these determinations will be performed on samples obtained during the child's routine care. No extra intervention is planned as part of this study.\n\nSamples and clinical data will be collected at different time points after transplantation. Schematically, collection is planned for months 0, 1, 3, 6, 12 and 24 post-transplant. In addition to these pre-established points, comprehensive data collection will be attempted when the child suffers a relevant clinical event, e.g. infection, treatment toxicity, organ rejection (post-transplant complication).",[60,61,62],"Transplant Complication","Kidney Transplant","Liver Transplant",[64,65,66,67],"observational","epigenomic analysis","genomic analysis","european health data space","NOT_YET_RECRUITING","2025-09-25",{"date":71,"type":38},"2025-09-26",{"date":73,"type":22},"2025-09-30",{"date":75,"type":22},"2028-01",{"name":44,"class":45},4,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},"100570609","phase-1-phase-i-clinical-trial-of-cart-cell-therapy-for-refractoryrelapsed-acute-lymphoblastic-leukemia-in-children-adolescents-and-young-adults-100570609","NCT06709469","Phase I Clinical Trial of CART Cell Therapy for Refractory\u002FRelapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults","A Phase I Clinical Trial of CART Cell Therapy for Refractory\u002F Relapsed Acute Lymphoblastic Leukemia With Unmet Needs in Children, Adolescents and Young Adults: Feasibility and Safety Study (REALL_CART).","REALL_CART","Inclusion Criteria:\n\n* ARM A: CD19+\u002F- CD22+ B-ALL with relapsed or refractory disease not responding to conventional chemotherapy and with no other curative therapy available. Treatment with previous CART CD19 therapy is permitted, but is not mandatory, OR:\n* ARM B: T-ALL with relapsed or refractory disease not responding to conventional chemotherapy and with no other curative therapy available.\n* Patients diagnosed with ALL must be suitable for allogeneic HSCT and willing to proceed to transplant if the CART treatment induces complete remission and the investigator believes it is the best option.\n* For ARM B there must be a suitable haploidentical donor (following local standard operating procedures).\n* Lansky (age \\\u003C16 years) or Karnofsky (age ≥16 years) score of 50 or greater.\n* Life expectancy greater than 12 weeks.\n* Absolute neutrophil count (ANC) ≥ 500\u002FμL unless, in the opinion of the investigator, cytopenia is due to underlying leukemia and is potentially reversible with leukemia therapy.\n* Platelet count ≥ 50,000\u002FμL unless, in the opinion of the investigator, cytopenia is due to underlying leukemia and is potentially reversible with leukemia therapy.\n* Absolute lymphocyte count ≥ 100\u002FμL.\n* Adequate renal, hepatic, pulmonary, and cardiac function.\n* Adequate venous access and absence of contraindications for lymphoapheresis\n* Patients with a seizure disorder may be enrolled if well controlled with anticonvulsants.\n* Patients or patients' legal representative, parent(s), or guardian able to provide written informed consent.\n\nExclusion Criteria:\n\n* Enrolled in another clinical trial in the previous 4 weeks.\n* Active infection requiring systemic medical therapy including clinically significant viral infection or uncontrolled viral reactivation of EBV, CMV, adenovirus, BK-virus, HHV-6 or Aspergillus.\n* Any of the following cardiac criteria: cardiac echocardiography with LVSF\\\u003C30% or LVEF\\\u003C40%; or clinically significant pericardial effusion.\n* Presence of CNS-3 disease or uncontrolled seizure disorder.\n* Active immunosuppressive therapy with the exception of prednisone 10 mg\u002Fday (or equivalent), within 7 days prior to enrolment.\n* GFR \\\u003C30 ml\u002Fmin or bilirubin \\>3 times the upper limit of normality (unless due to Gilbert's syndrome).\n* Any other condition that, in the opinion of the PI, may interfere with the efficacy and\u002For safety evaluation of the trial.\n* Pregnant or lactating women.\n* Sexually active patients must be willing to utilize one of the more effective birth control methods for at least 12 months after the infusion and until CAR-T cells are no longer present on two consecutive tests. Male partner should use a condom. Women of child-bearing potential are defined as all women physiologically capable of becoming pregnant.\n* Sexually active males should use a condom during intercourse for at least 12 months after the infusion and until CAR-T cells are no longer present on two consecutive tests.","30 Years",{"count":88,"type":22},10,[90],"PHASE1","The goal of this clinical trial is to test the feasibility and safety of an academic production of two different anti-CD19 chimeric antigen receptor T cells (CART) products according to the different biomarkers of the disease in children and young adults with relapsed\u002Frefractory CD19+ B cell acute lymphoblastic leukemia (r\u002Fr B-ALL) or relapsed\u002Frefractory T-cell acute lymphoblastic leukemia (r\u002Fr T-ALL). The main questions it aims to answer are:\n\n1. The safety and feasibility of autologous CART-19\u002F22 in children, adolescents and young adults with a CD19+\u002F- CD22+ relapse\u002F refractory disease for a r\u002Fr B-ALL.\n2. The safety and feasibility of allogeneic CART-NKG2D (chimeric-antigen receptor Natural-killer group 2, member D) in children, adolescents and young adults with r\u002Fr T-ALL.",[93],"Precursor Cell Lymphoblastic Leukemia-Lymphoma","2025-09-19",{"date":96,"type":38},"2025-09-22",{"date":98,"type":38},"2025-07-08",{"date":100,"type":22},"2030-12-01",{"name":44,"class":45},1,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":114,"conditions":115,"keywords":119,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":102},"100570021","phase-4-effectiveness-and-cost-effectiveness-of-a-pre-emptive-genotyping-strategy-in-patients-receiving-tacrolimus-100570021","NCT06701825","Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus","A Multicentre, Controlled, Randomised and Single-blind, Adaptive Phase IV Protocol to Evaluate Effectiveness and Cost-effectiveness of Pre-emptive Genotyping Strategy to Optimise Tacrolimus Dosage in a Pretransplant Chronic Kidney Disease Population Cohort","TRANSPGx","Inclusion Criteria:\n\n1. Participants must be willing and able to provide written informed consent prior the initiation of any study procedures.\n2. Subject or their legally authorized representative has voluntarily signed the informed consent document.\n3. Participant is on the waiting list for a kidney transplant.\n4. Subject is able and willing to take part and be followed-up for the majority of the study duration, and adhere to the procedures specified in this protocol.\n5. Subjects must be naïve to any genotyping test of the following genes: CYP3A5.\n\nExclusion Criteria:\n\n1. Known hypersensitivity\u002Fallergy reaction to tacrolimus or any of the excipients.\n2. History of renal, heart, and\u002For liver transplant.\n3. History or clinical evidence of any disease and\u002For existence of any surgical or medical condition, which might interfere in a relevant manner with the absorption, distribution, metabolism, or excretion of the study treatment, except for renal disease.\n4. Any condition or situation precluding or interfering the compliance with the protocol.\n5. Any condition at medical discretion for which renal transplantation and\u002For study treatment should not be received.",{"count":112,"type":22},114,[25],"This is a phase IV multicentre adaptive single-blinded randomized clinical trial to evaluate if preemptively genotyping populations at pretransplant chronic kidney disease susceptible of receiving tacrolimus therapy is effective, cost-effective, and feasible within the Spanish National Health System when compared to the current standard of care. This trial is nested within the iPHARMGx master protocol.",[116,117,118],"Kidney Disease, Chronic","Transplant Recipient (Kidney)","Immunosuppression",[120,121,122,123,124],"Tacrolimus","Kidney transplant","Cost-effectiveness","Pharmacogenetic","Phase IV Clinical Trial","2025-09-04",{"date":127,"type":38},"2025-09-11",{"date":129,"type":38},"2025-06-02",{"date":131,"type":22},"2026-12-31",{"name":44,"class":45},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":140,"targetDuration":54,"studyType":57,"phases":4,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},"100514859","no-biopsy-approach-in-celiac-disease-cut-off-points-for-iga-anti-tissue-transglutaminase-assays-100514859","NCT05983978","No-biopsy Approach in Celiac Disease: Cut-off Points for IgA Anti-tissue Transglutaminase Assays","No-biopsy Approach for the Diagnosis of Celiac Disease: Definition of Cut-off Points for Different IgA Anti-tissue Transglutaminase Assays","Inclusion criteria:\n\n* Patients, on gluten-containing diet, with TGt-IgA antibodies \\> Upper Limit of Normal (ULN) and intestinal biopsy confirming celiac disease (CD).\n* Patients with TCRγδ+ \\>10% combined with decrease NK-like intraepithelial lymphocytes in the intestinal epithelium.\n* Paediatric patients who meet ESPGHAN criteria (TGt-IgA antibodies \\>10xULN) without duodenal biopsy performed.\n\nExclusion criteria:\n\n* Patients already diagnosed with CD.\n* Patients who refused duodenal biopsy.\n* Patients with primary or secondary immunodeficiencies.\n* Patients with malignancy.\n* Recruited patients whose remaining serum cannot be sent to the reference centre, whose biopsies are of poor quality or who nod not sign the informed consent from.",{"count":141,"type":22},150,"The main objective of this multicenter and observational study is to define the optimal threshold of different commercially available IgA anti-transglutaminase (tTG-IgA) antibody assays for celiac disease diagnosis (CD) avoiding the need for an intestinal biopsy.\n\nThe main questions to be answered are:\n\n* Is the anti-tTG-IgA titer cut-off above 10 times the upper limit of normal (ULN) useful in all anti-tTG IgA assays?\n* Is the diagnostic performance of the newly defined cut-offs of anti-tTG-IgA the same in all the evaluated assays?\n* Is the dynamic of the anti-tTG-IgA levels after the introduction of the gluten-free diet (GFD) similar across the different assays included in the study?\n\nThis is a prospective multicenter study that will enroll pediatric and adult patients with new-onset CD during the years 2023 and 2024. Serum from these patients will be collected for the determination of anti-tTG-IgA according to the local methodology (participating hospital) and by the anti-tTG IgA assays most commonly used in our country, which will be centralized in the same reference center (Hospital Universitario La Paz).",[144],"Celiac Disease",[146,147],"anti-transglutaminase IgA","no-biopsy approach","2025-08-01",{"date":150,"type":38},"2025-08-06",{"date":152,"type":38},"2023-01-02",{"date":154,"type":22},"2026-03-31",{"name":44,"class":45},6,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":170,"conditions":171,"keywords":174,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":185},"100583624","phase-1-dose-finding-for-dobutamine-during-transitional-circulation-in-very-preterm-infants-100583624","NCT06878742","Dose-finding for Dobutamine During Transitional Circulation in Very Preterm Infants","Dose-finding for Dobutamine During Transitional Circulation in the Very Preterm Infant","NeoCirc-002","Inclusion Criteria:\n\n* Born with up to 32(+6) weeks gestation\n* Presence of hemodynamic insufficiency, defined as SVC flow \\\u003C51 ml\u002Fkg\u002Fmin.\n* Provision of signed and dated informed consent form by father\u002Fmother or legally designated representative, which can be given antenatally.\n\nExclusion Criteria:\n\n* Neonates considered non-viable, with a clinical decision not to provide life support\n* Infants with severe congenital hydrops fetalis needing chest or peritoneal drainage before recruitment\n* Infants already on dobutamine treatment\n* Infants with congenital malformations likely to affect cardiovascular adaptation (including: congenital diaphragmatic hernia, gastroschisis or congenital heart defects)\n* Infants with chromosomal anomalies\n* Lack of parental signed informed consent","72 Hours",{"count":167,"type":22},30,[90,169],"PHASE2","Single centre, dose finding trial to establish the minimum effective dose of dobutamine required to treat hemodynamic insufficiency, defined as low superior vena cava (SVC) flow, in infants below 33 weeks' gestation during transitional circulation (first 72 hours from birth).",[172,173],"Infant, Premature, Diseases","Circulatory and Respiratory Physiological Phenomena",[175,176],"Hemodynamic insuffiency","Low superior vena cava flow","2025-03-10",{"date":179,"type":38},"2025-03-17",{"date":181,"type":38},"2024-06-24",{"date":183,"type":22},"2029-06",{"name":44,"class":45},3,{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":23,"phases":196,"briefSummary":197,"conditions":198,"keywords":203,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":4},"100558815","phase-4-a-multicentre-randomised-single-blind-controlled-protocol-to-evaluate-the-efficacy-of-early-administration-of-botulinum-toxin-for-primary-midline-closure-in-patients-with-open-abdomen-100558815","NCT06556030","A Multicentre, Randomised, Single-blind, Controlled Protocol to Evaluate the Efficacy of Early Administration of Botulinum Toxin for Primary Midline Closure in Patients With Open Abdomen.","Botulinum Toxin in Open Abdomen Closure","BOTU-CLOSURE","Inclusion Criteria:\n\n* 1\\. Subjects must be able to understand the purpose and risks of the study, giving informed consent and authorising the use of confidential health information. If the patient is unable to consent due to emergency status, a first or second degree relative will be requested. If the patient recovers, the patient\\'s consent to continue participation will be sought again.\n\n  2\\. Subjects Patients over 18 years of age who, regardless of the cause, have undergone abdominal surgery, after which it has been necessary to leave the abdomen open.\n\n  3\\. Subjects able and willing to participate and to be followed for most of the duration of the study.\n\nExclusion Criteria:\n\n* Personal historyDiseases which, in the opinion of the investigator, may interfere with or worsen the action of the botulinum toxin. For example, patients with: hyperthyroidism, neuromuscular disease, myasthenia gravis, Eaton Lamber syndrome or ALS are excluded.\n\n  2\\. Drugs that affect muscle tone or the autonomic nervous system, e.g. administration of antibiotics such as aminoglycosides, lincosamides, polymyxins or tetracyclines.\n\n  3\\. Pregnancy or lactation. 4. Known hypersensitivity. 5. Active neoplastic disease.",{"count":195,"type":22},50,[25],"A multicentre, randomised, single-blind, controlled protocol to evaluate the efficacy of early administration of botulinum toxin for primary midline closure in patients with open abdomen. Early use (less than 48 hours) of botulinum toxin as a neuromuscular abdominal wall blocker in patients whose abdomen is left open, regardless of the cause, will improve postoperative outcome and prognosis, leading to significantly higher percentages of primary midline closure.",[199,200,201,202],"Botulinum Toxin Type A","Open Abdomen","Abdominal Wall","Clinical Trial",[204],"botulinum toxin, open abdomen, laparostomy, abdominal wall closure, clinical trial.","2024-08-13",{"date":207,"type":38},"2024-08-15",{"date":209,"type":22},"2025-01",{"date":211,"type":22},"2026-12",{"name":44,"class":45},{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":102},"100553654","phase-2-abdominal-aortic-aneurysm-stabilization-with-truncal-cells-controlled-clinical-trial-with-historical-cohorts-100553654","NCT06488898","Abdominal Aortic Aneurysm Stabilization With Truncal Cells: Controlled Clinical Trial With Historical Cohorts","Inclusion Criteria:\n\n1. Subjects with AAA greater than 5 cm diameter with endovascular treatment indication, analyzed by aortic AngioCT.\n2. Subjects ≥ 18 years at the time of inclusion.\n3. Subjects with a good infrarenal neck for a standard device placement, neither fenestrated nor branched.\n4. Patients with an estimated life expectancy greater than 2 years at the time of inclusion.\n5. Women with childbearing capacity must have a negative pregnancy test at the time of inclusion and must agree to use highly effective contraceptive methods (diaphragms plus spermicide or male condom plus spermicide, oral contraceptive combined with a second method contraceptive implant, injectable contraceptive, permanent intrauterine device, sexual abstinence or partner with vasectomy) during their study participation.\n6. The patient must be able to attend all study visits and comply with all study procedures.\n\nExclusion Criteria:\n\n1. Patients with unresolved neoplasia history or hematologic disease.\n2. Patients with uncontrolled arterial hypertension (≥180\u002F110) at the time of inclusion.\n3. Patients with severe heart failure (New York Heart Association \\[NYHA\\] IV) or ejection fraction \\\u003C20%.\n4. Patients with malignant ventricular arrhythmias\n5. Patients with deep vein thrombosis the last three months\n6. Patient with active sepsis at the time of inclusion\n7. Patients with acute myocardial infarction or stroke in the previous month\n8. Any type of medical or psychiatric illness that, in investigator opinion, could be a reason for exclusion from the study.\n9. Patient with major surgery or severe craniocerebral trauma in the 3 months prior to inclusion in the study.\n10. Administration of any investigational drug at the time of inclusion or in the 3 months prior\n11. Infants or pregnant women\n12. Transplanted patients.",{"count":220,"type":22},8,[169],"Phase IIa, single-center clinical trial compared with historical cohorts to evaluate the preliminary safety and efficacy of an allogeneic adipose tissue-derived mesenchymal stem cells infusion in an aneurysmal sac for the treatment of AAA.",[224],"Aortic Aneurysm, Abdominal","2024-07-04",{"date":227,"type":38},"2024-07-08",{"date":229,"type":38},"2024-06-13",{"date":231,"type":22},"2025-12-31",{"name":44,"class":45},{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":241,"targetDuration":4,"studyType":23,"phases":243,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":259,"locationsCount":4},"100537090","towards-telemonitoring-in-immune-mediated-inflammatory-diseases-implementation-of-a-mixed-attention-model-imidoc-100537090","NCT06273306","Towards Telemonitoring in Immune-Mediated Inflammatory Diseases: Implementation of a Mixed Attention Model (IMIDOC)","Towards Telemonitoring in Immune-Mediated Inflammatory Diseases: Implementation of a Mixed Attention Model","IMIDOC","Inclusion Criteria:\n\n* Clinical diagnosis with Rheumatoid Arthritis or Spondylarthritis\n* Treatment with biologic or targeted disease modifying antirheumatic drugs.\n* Ability to use smartphone.\n\nExclusion Criteria:\n\n* only patients with conditions that hinder or prevent the use of a mobile application (blindness, mental retardation, dementia, digitalfilliteracy).",{"count":242,"type":22},360,[244],"NA","The main objective is to evaluate the implementation of a hybrid care model called the mixed attention model (MAM) in clinical practice and to evaluate whether its implementation improves clinical outcomes compared to conventional follow-up.\n\nThis is a multicenter prospective observational study involving 360 patients with rheumatoid arthritis (RA) and Spondylarthritis (SpA) from five Spanish Hospitals. Patients will be followed-up by the MAM protocol, which is a care model that incorporates the use of digital tool consisting of a mobile application (App) that patients can use at home and that professionals can review asynchronously to detect incidents and to follow their patients; clinical evolution between face-to-face visits. Another group of patients, whose follow-up will be conducted in accordance with a traditional face-to-face care model, will be assessed as the control group. Sociodemographic characteristics, treatments, laboratory parameters, assessment of tender and swollen joints, visual analogue scale for pain and electronic patient reported outcome reports (ePROs) will be collected for all subjects. In the MAM group, these items will be self-assessed both by the mobile App and during face-to-face visits with rheumatologist, who will do the same for patients included in the traditional care model. Patients will be able to report any incidence related to their disease or treatment through the mobile App.",[247,248,249,250,251,252],"Telemedicine","Telehealth","eHealth","Rheumatic Diseases","Arthritis, Rheumatoid","Spondylarthritis","2024-02-15",{"date":255,"type":38},"2024-02-22",{"date":257,"type":22},"2024-03-15",{"date":131,"type":22},{"name":44,"class":45},""]